AstraZeneca’s senior vice-president and head of precision medicine, research & development, Ruth March, has been central to the company’s transformed approach to personalised treatment.
We are in the most competitive period ever for the pharmaceutical industry, characterised by incremental innovation and looming patent cliffs – and path-to-market strategy firm IDEA Pharma
Johnson & Johnson’s global head of external innovation, William 'Bill' Hait, describes innovation as often being “an overnight success you’ve worked on for many years”.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl